Big REVEAL: Merck's Anacetrapib Surprises With Success, But What Next?
Executive Summary
Merck & Co has triumphed against the odds announcing positive top-line results from the cardiovascular outcomes trial of its CETP inhibitor anacetrapib. But questions remain about the level of benefit and the regulatory prospects.
You may also be interested in...
Merck Calls It Quits On Anacetrapib
Despite the success in the REVEAL outcomes trial for the cholesteryl ester transfer protein (CETP) inhibitor, Merck will not submit the cholesterol therapy for regulatory approval.
Merck's Keytruda Claims Market Leadership In First-line Lung Cancer
Merck enjoyed a good second quarter, beating sales expectations for Keytruda and other drugs, which helped offset losses related to patent expirations.
2Q Pharma Results Preview: Bristol, AstraZeneca, Roche, Celgene, Bayer, Merck, AbbVie & Sanofi
PD-1 inhibitor performance and the intense curiosity around AstraZeneca both for its MYSTIC trial and Soriot's faithfulness to the company are key themes at the half-year mark. Eyes are also on commercial performance for Roche's Ocrevus and Merck's anacetrapib for clarity on whether it has a commercial future.